Search Result

Results for "

181C

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (1) Endogenous Metabolite (1) HIV (9) Isotope-Labeled Compounds (1) MicroRNA (12) Reverse Transcriptase (3)
By Research Areas:	Cancer (3) Infection (9) Inflammation/Immunology (1) Metabolic Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-R00333

*hsa-miR-181c-3p mimic*	MicroRNA	Cancer
hsa-miR-181c-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-181c-3p mimic hsa-miR-181c-3p mimic

HY-R00334

*hsa-miR-181c-5p mimic*	MicroRNA	Cancer
hsa-miR-181c-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-181c-5p mimic hsa-miR-181c-5p mimic

HY-R02698

*mmu-miR-181c-3p mimic*	MicroRNA	Cancer
mmu-miR-181c-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-181c-3p mimic mmu-miR-181c-3p mimic

HY-RI00333

*hsa-miR-181c-3p inhibitor*	MicroRNA
hsa-miR-181c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-181c-3p inhibitor hsa-miR-181c-3p inhibitor

HY-RI00334

*hsa-miR-181c-5p inhibitor*	MicroRNA
hsa-miR-181c-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-181c-5p inhibitor hsa-miR-181c-5p inhibitor

HY-RI02698

*mmu-miR-181c-3p inhibitor*	MicroRNA
mmu-miR-181c-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-181c-3p inhibitor mmu-miR-181c-3p inhibitor

HY-R00333A

*hsa-miR-181c-3p agomir*	MicroRNA
hsa-miR-181c-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-181c-3p agomir hsa-miR-181c-3p agomir

HY-R00334A

*hsa-miR-181c-5p agomir*	MicroRNA
hsa-miR-181c-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-181c-5p agomir hsa-miR-181c-5p agomir

HY-R02698A

*mmu-miR-181c-3p agomir*	MicroRNA
mmu-miR-181c-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-181c-3p agomir mmu-miR-181c-3p agomir

HY-RI00333A

*hsa-miR-181c-3p antagomir*	MicroRNA
hsa-miR-181c-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-181c-3p antagomir hsa-miR-181c-3p antagomir

HY-RI00334A

*hsa-miR-181c-5p antagomir*	MicroRNA
hsa-miR-181c-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-181c-5p antagomir hsa-miR-181c-5p antagomir

HY-RI02698A

*mmu-miR-181c-3p antagomir*	MicroRNA
mmu-miR-181c-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-181c-3p antagomir mmu-miR-181c-3p antagomir

HY-141578

C18:1-Ceramide

Endogenous Metabolite Metabolic Disease

C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes

C18:1-Ceramide	Endogenous Metabolite	Metabolic Disease
C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes

HY-150599

HIV-1 inhibitor-43	HIV DNA/RNA Synthesis	Infection
HIV-1 inhibitor-43 is a potent HIV-1 inhibitor with an EC₅₀ of 21.3 nM, 6.2 nM, < 0.7 nM and < 0.7 nM for Y188L, K103N-Y181C, K103N and Y181C, respectively. HIV-1 inhibitor-43 can reduce HIV-1 RNA and protein p24 expression .

HY-141578S

C18:1-Ceramide-13C18

Isotope-Labeled Compounds Others

C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

C18:1-Ceramide-13C18	Isotope-Labeled Compounds	Others
C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

HY-116528

GCA-186	HIV	Infection
GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC₅₀s of 1, 180, 1, and 40 nM for III_B, III_B-R(Y181C), NL4-3 and NL4-3_K103N of HIV-1 strains, respectively .

HY-146365

HIV-1 inhibitor-30	HIV	Infection Inflammation/Immunology
HIV-1 inhibitor-30 (compound 10i) is a potent HIV-1 inhibitor with an EC₅₀ value of 40 nM and an IC₅₀ value of 80 nM for HIV-1 RT DNA polymerase. HIV-1 inhibitor-30 has highly antiretroviral activity against seven non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains (RT-K103N; RT-Y181C; RT-K103N,Y181C; RT-L100I,K103N; RT-Y188L; RT-K103N,G190A; RT-K103N,V108I) with IC₅₀s of 0.04~1.42 μM. HIV-1 inhibitor-30 can be used for researching AIDS .

HY-16767

Doravirine 5+ Cited Publications MK-1439	HIV Reverse Transcriptase	Infection
Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and *Y181C* reverse transcriptase mutants, respectively .

HY-W325699

HIV-1 inhibitor-48	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-48 (compound 13o) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and exhibits anti-HIV-1 activity .

HY-144122

HIV-1 inhibitor-15	HIV	Infection
HIV-1 inhibitor-15 (compound 9d) is a highly potent and broad-spectrum HIV-1 inhibitor. HIV-1 inhibitor-15 has inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, E138K with EC₅₀s of 1.7 nM, 4 nM, 2 nM, 6 nM and 9 nM, respectively. HIV-1 inhibitor-15 has good solubility, safety profiles and favorable oral bioavailability .

HY-144123

HIV-1 inhibitor-16	HIV	Infection
HIV-1 inhibitor-16 (compound 7a) is a highly potent HIV-1 inhibitor with an EC₅₀ value of 1.3 nM for HIV-1 WT. HIV-1 inhibitor-16 also has certain inhibitory activity against HIV-1 K103N, E138K, Y181C and L100I strains with EC₅₀s of 5.4 nM, 9.2 nM, 22 nM and 35 nM. HIV-1 inhibitor-16 has favorable solubility and liver microsome stability, and does not exhibit apparent CYP enzymatic inhibitory activity or acute toxicity .

HY-152161

HIV-1 inhibitor-51	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (K_D=2.50 μM) and inhibitory activity (IC₅₀=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC₅₀s of 2.22-53.3 nM for mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056) .

HY-146019A

HIV-1 inhibitor-25	HIV	Infection
HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC₅₀ value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC₅₀ of 13.6 nM, and exhibits relatively low cytotoxicity with a CC₅₀ of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC₅₀ of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141578

C18:1-Ceramide	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes

Cat. No.	Product Name	Chemical Structure

HY-141578S

C18:1-Ceramide-13C18

C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

C18:1-Ceramide-13C18
C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks